physostigmine has been researched along with Diabetes Mellitus, Adult-Onset in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashraf, M; Bajda, M; Hussain, S; Khan, IU; Mustafa, G; Mutahir, S; Rehman, TU; Riaz, S; Shaukat, A; Yar, M | 1 |
| Greig, NH; Kamal, MA; Nawaz, MS; Rashid, S; ul Ain, Q | 1 |
2 other study(ies) available for physostigmine and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Pyridine sulfonamide as a small key organic molecule for the potential treatment of type-II diabetes mellitus and Alzheimer's disease: In vitro studies against yeast α-glucosidase, acetylcholinesterase and butyrylcholinesterase.
Topics: Acetylcholinesterase; alpha-Glucosidases; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Molecular Docking Simulation; Molecular Structure; Pyridines; Saccharomyces cerevisiae; Structure-Activity Relationship; Sulfonamides | 2015 |
Exploring N(1)-p-fluorobenzyl-cymserine as an inhibitor of 5-lipoxygenase as a candidate for type 2 diabetes and neurodegenerative disorder treatment.
Topics: Amino Acid Sequence; Arachidonate 5-Lipoxygenase; Binding Sites; Diabetes Mellitus, Type 2; Humans; Lipoxygenase Inhibitors; Models, Molecular; Molecular Docking Simulation; Molecular Targeted Therapy; Mutation; Neurodegenerative Diseases; Neuroprotective Agents; Physostigmine; Protein Conformation; Protein Stability | 2014 |